Fenwick represented SciNeuro Pharmaceuticals, a leading neuromedicine company, in its $100 million Series A financing. The round was co-led by Lilly Asia Ventures Fund and Arch Venture Partners. They were joined by Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital and Zoo Capital.
SciNeuro will use the funding to build and advance a central nervous system (CNS) product portfolio with initial focus on the Greater China region. More information can be obtained from its announcement.
The Fenwick transaction team included corporate partner Matthew Rossiter, and associates James Li and Summer Yin.